Eli Lilly CEO David Ricks on Q1 earnings: This will be a year of both growth and investment

Eli Lilly CEO on weight loss drugs outlook: Our top priority is making more productПодробнее

Eli Lilly CEO David Ricks explains Q1 earnings miss, lowered forecastПодробнее

Eli Lilly CEO David Ricks breaks down Q1 earnings, obesity drug trial resultsПодробнее

Eli Lilly CEO David Ricks on Q3 earnings beat, Mounjaro strengthПодробнее

Eli Lilly CEO David Ricks on GLP-1 and obesity drugsПодробнее

Eli Lilly CEO David Ricks breaks down second-quarter earnings and drug pipelineПодробнее

Vast utility for weight loss drugs will more than pay for themselves, says Eli Lilly CEO David RicksПодробнее

Eli Lilly CEO weighs in on Q4 revenue missПодробнее

Eli Lilly CEO: Alzheimer's drug trial shows slowed disease progression by 40-60% in early patientsПодробнее

Eli Lilly CEO on quarterly earnings beat, pharma policy, and moreПодробнее

Eli Lilly CEO on slashing insulin prices, approval timelines for weight-loss and Alzheimer's drugsПодробнее

Watch CNBC's full interview with Eli Lilly CEO David RicksПодробнее

Eli Lilly is a 'multi-diversified drugmaker', says Cantor Fitzgerald's Louise ChenПодробнее

Eli Lilly stock soars on earnings, 'off-the-charts' demand for weight-loss drugsПодробнее

Eli Lilly CEO: We expect to launch five new medicines in 2022Подробнее

Eli Lilly CEO reacts to Q3 earnings miss, provides pipeline updateПодробнее

Eli Lilly CEO on Q2 earnings and core business performanceПодробнее

April 2022 - Dave Ricks | Eli Lilly and CompanyПодробнее

Billionaire investor Ken Langone: Lilly will be the first trillion dollar drug company in historyПодробнее